INAB - IN8bio, Inc. Common Stock

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
2.14 -0.03 (-1.4%)	---	---	---	---	-0.02 (-0.93%)	-0.02 (-0.94%)	-0.02 (-0.94%)

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

Market Period: Closed

Earnings & Ratios

Basic EPS:: -1.24
Diluted EPS:: -1.24
Basic P/E:: -1.7016
Diluted P/E:: -1.7016
RSI(14) 1m:: 45.45
VWAP:: 2.13
RVol:: 0.3259

Events

Period	Kind	Movement	Occurred At
1m	Price decrease 1m	2.11 -0.06 (-2.76%)	Oct 15 18:35
1m	Price decrease 1m	2.12 -0.03 (-1.4%)	Oct 15 15:59
1m	Price increase 1m	2.17 +0.02 (+1.17%)	Oct 15 15:11
1m	Price decrease 1m	2.15 -0.03 (-1.38%)	Oct 15 13:27
1m	Price decrease 1m	2.17 -0.02 (-1.02%)	Oct 15 11:17